Overexpression of p34(cdc2) protein kinase in epithelial ovarian carcinoma

B. A. Barrette, P. J. Srivatsa, William Arthur Cliby, Gary Keeney, Vera Jean Suman, K. C. Podratz, P. C. Roche

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To investigate the role of expression of p34(cdc2) protein kinase in normal, benign, and malignant ovarian epithelium. Material and Methods: Tissue sections from 24 patients with epithelial ovarian carcinoma (EOC) along with 6 normal ovarian specimens and 12 benign cystadenomas were incubated with mouse IgG monoclonal antibody to human p34(cdc2) protein kinase, followed by detection with use of a standard peroxidase-labeled streptavidin-biotin technique. Immunohistochemical staining was graded and compared. Clinical data were also reviewed: Results: Normal surface epithelium and 10 of 12 benign cystadenomas failed to stain for p34(cdc2) protein kinase. Of the 24 EOC specimens, however, 19 (79%) stained positively. The staining pattern or intensity has not associated with the histologic grade or surgical stage. Conclusion: Expression of p34(cdc2) protein kinase is strongly up-regulated in most cases of EOC but not in normal epithelial ovarian tissue or in most cases of benign epithelial tumors evaluated. Therefore, it may be associated with early events in carcinogenesis. Redundant overexpression of cyclin-dependent kinases such as p34(cdc2) may contribute to deranged cell cycle progression and proliferation of EOC. Observation of overexpression of p34(cdc2) protein kinase in other malignant lesions suggests a common mechanism.

Original languageEnglish (US)
Pages (from-to)925-929
Number of pages5
JournalMayo Clinic Proceedings
Volume72
Issue number10
StatePublished - 1997

Fingerprint

CDC2 Protein Kinase
Protein Kinases
Carcinoma
Cystadenoma
Epithelium
Staining and Labeling
Streptavidin
Cyclin-Dependent Kinases
Biotin
Peroxidase
Cell Cycle
Carcinogenesis
Coloring Agents
Immunoglobulin G
Monoclonal Antibodies
Cell Proliferation
Observation
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Barrette, B. A., Srivatsa, P. J., Cliby, W. A., Keeney, G., Suman, V. J., Podratz, K. C., & Roche, P. C. (1997). Overexpression of p34(cdc2) protein kinase in epithelial ovarian carcinoma. Mayo Clinic Proceedings, 72(10), 925-929.

Overexpression of p34(cdc2) protein kinase in epithelial ovarian carcinoma. / Barrette, B. A.; Srivatsa, P. J.; Cliby, William Arthur; Keeney, Gary; Suman, Vera Jean; Podratz, K. C.; Roche, P. C.

In: Mayo Clinic Proceedings, Vol. 72, No. 10, 1997, p. 925-929.

Research output: Contribution to journalArticle

Barrette, BA, Srivatsa, PJ, Cliby, WA, Keeney, G, Suman, VJ, Podratz, KC & Roche, PC 1997, 'Overexpression of p34(cdc2) protein kinase in epithelial ovarian carcinoma', Mayo Clinic Proceedings, vol. 72, no. 10, pp. 925-929.
Barrette, B. A. ; Srivatsa, P. J. ; Cliby, William Arthur ; Keeney, Gary ; Suman, Vera Jean ; Podratz, K. C. ; Roche, P. C. / Overexpression of p34(cdc2) protein kinase in epithelial ovarian carcinoma. In: Mayo Clinic Proceedings. 1997 ; Vol. 72, No. 10. pp. 925-929.
@article{ec7408306d3d43e1bd4be13d090a7f51,
title = "Overexpression of p34(cdc2) protein kinase in epithelial ovarian carcinoma",
abstract = "Objective: To investigate the role of expression of p34(cdc2) protein kinase in normal, benign, and malignant ovarian epithelium. Material and Methods: Tissue sections from 24 patients with epithelial ovarian carcinoma (EOC) along with 6 normal ovarian specimens and 12 benign cystadenomas were incubated with mouse IgG monoclonal antibody to human p34(cdc2) protein kinase, followed by detection with use of a standard peroxidase-labeled streptavidin-biotin technique. Immunohistochemical staining was graded and compared. Clinical data were also reviewed: Results: Normal surface epithelium and 10 of 12 benign cystadenomas failed to stain for p34(cdc2) protein kinase. Of the 24 EOC specimens, however, 19 (79{\%}) stained positively. The staining pattern or intensity has not associated with the histologic grade or surgical stage. Conclusion: Expression of p34(cdc2) protein kinase is strongly up-regulated in most cases of EOC but not in normal epithelial ovarian tissue or in most cases of benign epithelial tumors evaluated. Therefore, it may be associated with early events in carcinogenesis. Redundant overexpression of cyclin-dependent kinases such as p34(cdc2) may contribute to deranged cell cycle progression and proliferation of EOC. Observation of overexpression of p34(cdc2) protein kinase in other malignant lesions suggests a common mechanism.",
author = "Barrette, {B. A.} and Srivatsa, {P. J.} and Cliby, {William Arthur} and Gary Keeney and Suman, {Vera Jean} and Podratz, {K. C.} and Roche, {P. C.}",
year = "1997",
language = "English (US)",
volume = "72",
pages = "925--929",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Overexpression of p34(cdc2) protein kinase in epithelial ovarian carcinoma

AU - Barrette, B. A.

AU - Srivatsa, P. J.

AU - Cliby, William Arthur

AU - Keeney, Gary

AU - Suman, Vera Jean

AU - Podratz, K. C.

AU - Roche, P. C.

PY - 1997

Y1 - 1997

N2 - Objective: To investigate the role of expression of p34(cdc2) protein kinase in normal, benign, and malignant ovarian epithelium. Material and Methods: Tissue sections from 24 patients with epithelial ovarian carcinoma (EOC) along with 6 normal ovarian specimens and 12 benign cystadenomas were incubated with mouse IgG monoclonal antibody to human p34(cdc2) protein kinase, followed by detection with use of a standard peroxidase-labeled streptavidin-biotin technique. Immunohistochemical staining was graded and compared. Clinical data were also reviewed: Results: Normal surface epithelium and 10 of 12 benign cystadenomas failed to stain for p34(cdc2) protein kinase. Of the 24 EOC specimens, however, 19 (79%) stained positively. The staining pattern or intensity has not associated with the histologic grade or surgical stage. Conclusion: Expression of p34(cdc2) protein kinase is strongly up-regulated in most cases of EOC but not in normal epithelial ovarian tissue or in most cases of benign epithelial tumors evaluated. Therefore, it may be associated with early events in carcinogenesis. Redundant overexpression of cyclin-dependent kinases such as p34(cdc2) may contribute to deranged cell cycle progression and proliferation of EOC. Observation of overexpression of p34(cdc2) protein kinase in other malignant lesions suggests a common mechanism.

AB - Objective: To investigate the role of expression of p34(cdc2) protein kinase in normal, benign, and malignant ovarian epithelium. Material and Methods: Tissue sections from 24 patients with epithelial ovarian carcinoma (EOC) along with 6 normal ovarian specimens and 12 benign cystadenomas were incubated with mouse IgG monoclonal antibody to human p34(cdc2) protein kinase, followed by detection with use of a standard peroxidase-labeled streptavidin-biotin technique. Immunohistochemical staining was graded and compared. Clinical data were also reviewed: Results: Normal surface epithelium and 10 of 12 benign cystadenomas failed to stain for p34(cdc2) protein kinase. Of the 24 EOC specimens, however, 19 (79%) stained positively. The staining pattern or intensity has not associated with the histologic grade or surgical stage. Conclusion: Expression of p34(cdc2) protein kinase is strongly up-regulated in most cases of EOC but not in normal epithelial ovarian tissue or in most cases of benign epithelial tumors evaluated. Therefore, it may be associated with early events in carcinogenesis. Redundant overexpression of cyclin-dependent kinases such as p34(cdc2) may contribute to deranged cell cycle progression and proliferation of EOC. Observation of overexpression of p34(cdc2) protein kinase in other malignant lesions suggests a common mechanism.

UR - http://www.scopus.com/inward/record.url?scp=0030612241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030612241&partnerID=8YFLogxK

M3 - Article

C2 - 9379694

AN - SCOPUS:0030612241

VL - 72

SP - 925

EP - 929

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -